Gamida Cell Ltd.
Harey Yehuda 54
P.O.B. 94
Savyon
56530
Tel: 03-534-7482
Fax: 03-534-3067
215 articles about Gamida Cell Ltd.
-
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
2/23/2024
Gamida Cell Ltd. presented data highlighting its expanded access program for FDA-approved allogeneic stem cell therapy Omisirge® and Phase 1 data for its allogeneic cryopreserved natural killer cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.
-
Gamida Cell Actively Pursuing Strategic Alternatives - Jan 29, 2024
1/29/2024
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction.
-
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
1/17/2024
Gamida Cell Ltd. today announced it will present new data on its FDA approved allogeneic stem cell therapy Omisirge at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings.
-
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
11/20/2023
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.
-
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
11/14/2023
Gamida Cell Ltd today reported financial results for the quarter ended September 30, 2023, and provided a business update.
-
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
10/2/2023
Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California, and livestreamed globally.
-
First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)
9/27/2023
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the first patient has received a stem cell transplant with Omisirge.
-
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
8/14/2023
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update.
-
Gamida Cell to Report Second Quarter 2023 Financial Results
8/1/2023
Gamida Cell Ltd. today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023.
-
The FDA’s CBER approved nine novel therapies in the first half of 2023, with several more high-profile decisions on deck for the second half of the year.
-
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
7/11/2023
Gamida Cell Ltd. today announced the publication in press of a prospective sub-study of the Phase 3 clinical trial for Omisirge® (omidubicel-onlv), the company’s allogeneic stem cell transplant therapy, characterizing immune reconstitution kinetics following hematopoietic stem cell transplantation (HCT) with Omisirge compared to umbilical cord blood (UCB).
-
Gamida Cell To Host Investor Day
6/14/2023
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, will host an Investor Day on Thursday, June 29, 2023 beginning at 8 a.m. EDT in New York City, and will also be available via a live webcast.
-
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
5/31/2023
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET.
-
Gamida Cell Appoints Terry Coelho as CFO
5/22/2023
Gamida Cell Ltd. today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately.
-
Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
5/15/2023
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended March 31, 2023.
-
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
5/11/2023
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company.
-
Gamida Cell Announces Launch of Public Offering of Securities - April 19, 2023
4/19/2023
Gamida Cell Ltd. announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares.
-
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
4/19/2023
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share.
-
Omisirge is approved for patients who receive cord blood transplantation following myeloablative therapy.
-
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
3/27/2023
Gamida Cell Ltd. today provided a business update and reported financial results for the year ended December 31, 2022.